The evaluation of adverse drug reactions in Saudi Arabia: A retrospective observational study

Khalidah A. Alenzi a,⇑, Najah S. Alanazi b, Mohammed Almalki c, Homoud alomrani d, Fahad O. Alatawi e

a Ministry of Health, Regional Drug Information & Pharmacovigilance Center, Tabuk, Saudi Arabia
b Pharm D, University of Tabuk, Tabuk, Saudi Arabia
c Ministry of Health, Umlog Hospital, Tabuk, Saudi Arabia
d Ministry of Health, Haqel Hospital, Tabuk, Saudi Arabia
e Ministry of Health, King Fahad Specialist Hospital, Tabuk, Saudi Arabia

Abstract

Purpose: This study aimed to assess the type, severity, seriousness, reasons, and outcomes of adverse drug reactions (ADRs) in the reports submitted to the regional spontaneous ADR database.

Methods: A retrospective observational study was conducted to analyze all the Tabuk Health Affairs hospitals in Saudi Arabia submitted to SFDA from January 2020 to December 2020. The database was structured according to the Saudi ADR form's fields. The Naranjo algorithm was used to assess the causes of the ADRs (SFDA, 2022).

Results: For 1 year, 2,349 ADR reports, along with 242 suspected drugs for 4,114 reactions, were submitted to SFDA. We found more males than females had ADRs (56.1% vs. 43.8%, \( P < 0.05 \)).

Antimicrobial drugs (26.9%), hematologic drugs (19.7%), and neuropsychiatric drugs (12.9%) were responsible for most ADRs. Most of the reactions were associated with the use of ciprofloxacin (7.7%), followed by the combination of lopinavir and ritonavir (4.1%). Two deaths resulted from salbutamol and cefazolin use. Based on the results of the Naranjo assessment of causality, cardiovascular events (9.9%) exhibited the highest score (\( \geq 9 \)) for a causal relationship with the suspected drugs, followed by dermatological events (9.5%).

Conclusions: The spontaneous report database is an important and valuable source of aftermarket authorization safety information. In our study, most drugs used as antimicrobial, cardiovascular, and hematological therapies were associated with a higher risk of developing severe and serious events. We recommend monitoring and using medications optimally to ensure patient safety.

Keywords:
Adverse drug reactions
Naranjo scale
Pharmacovigilance

1. Introduction

The World Health Organization (WHO) defined "Pharmacovigilance" as "The science and activities related to the detection, assessment, understanding and prevention of adverse drug effects or any other possible drug-related problems." In 1961, after the thalidomide disaster, the WHO established its International Drug Monitoring Program in Uppsala at the country level. The American Society of Health-System Pharmacists defined an adverse drug reaction (ADR) as a nonpreventable adverse drug event that occur during the usual use of medication (Lee et al., 2022).

The spontaneous reporting system is the most widely used system that pharmaceutical companies, health care professionals, and patients use to report ADRs detected during treatment. These reports are submitted to the national authorities that regulate pharmacovigilance activities in the country.

Collecting spontaneous adverse events from health care providers or patients in a regional database helps to monitor medication

https://doi.org/10.1016/j.jsps.2022.03.018
sible ADR, and doubtful if 0 or less (Murayama et al., 2018). The patient outcomes were reported as recovered or not recovered. Additionally, we assessed which organ system the adverse reaction affected, the pharmacological classifications of the products involved, and the route of administration.

The ADRs’ severity was classified into hospitalization, required intervention to prevent permanent impairment or damage, disability occurring (disruption in the patient’s body function/structure, physical activities, or quality of life), required monitoring, or death. The comparative demographic and categorical variables were presented as frequencies (percentages) to achieve readily comparable information and quantify. At the same time, we calculated gender-specific incidence. All data were analyzed using Statistical Analysis Software, version 9.4.

3. Results

We analyzed spontaneous reports by collecting 2,349 reports of ADR cases for 4,114 reactions from January 2020 to December. The age group with the greatest number of patients (n = 519, 12.6%) was 41–50, followed by the group of patients aged 31–40 (n = 491, 11.9%), as shown in Table 1.

The majority of the studied population was male (n = 1,320, 56.1%; female: n = 1,029, 43.8%). Death occurred equally for both sexes. Nevertheless, among males, ADRs were more severe. We found males had ADRs that were more life-threatening (n = 8, 0.61%) and caused prolonged hospital stay (n = 590, 44.7%) or hospitalization (n = 169, 12.8%) more often when compared to females (n = 3, 0.29%, n = 296, 28.82%, n = 50, 4.8%, respectively), as shown in Fig. 1.

Two patients in the 50 and older group died due to ADR, and most of the life-threatening adverse reactions were associated with patients older than 60. Of the reactions, 96.69% of patients recovered, as shown inTables 1 and 2.

The antimicrobial category had the greatest number of suspected drugs associated with ADRs (n = 633, 26.9%), followed by hematological drugs (n = 461, 19.7%) and neuropsychiatric drugs (n = 301, 12.9%), as shown in Fig. 2.

Hematological and antimicrobial drugs led to four (0.17%) life-threatening cases. Hematologic drugs caused patient hospitalization in 2.3% of cases. Prolonged hospitalization was associated with the use of antimicrobial drugs (n = 280, 11.9%). Two deaths resulted from salbutamol and cefazolin use, as shown in Fig. 2.

Drugs resulting in the greatest number of ADRs were ciprofloxacin (7.7%) and the combination of lopinavir and ritonavir (4.1%). In 3,978 cases (96.7%), patients with reactions recovered, and only 128 (3.1%) did not recover. Most patients with ciprofloxacin-induced reactions recovered (n = 280, 6.8%), and (n = 36, 0.9%) did not recover (P < 0.05), as shown in Table 3.

The most frequently observed systemic events with a score of 9 or more, determined using the Naranjo causality assessment, were cardiac events (9.9%), dermatological events (9.5%), and renal events (7.5%). A score of 9 or greater indicates a highly probable adverse reaction, as shown in Table 4.

The highest medication reported as definite adverse event was ciprofloxacin (n = 198, 4.8%) followed by clarithromycin (n = 122, 2.97%). Gastrointestinal events (630; 15.3%) were the most common systemic event medication use caused in patients who often recovered, followed by hepatic events (516; 12.5%), as shown in Table 4.

4. Discussion

The present study found a relationship between older age and a more frequent number of ADRs, in contrast with other studies that extensively argued for the lack of relationship between older age
and ADRs (Beijer and de Blaey, 2002, Pillans, 2008). Many factors could make this age group more susceptible to ADRs, such as comorbidities, the inappropriate use of a prescription, insufficient monitoring, and polypharmacy (Lavan and Gallagher, 2016).

Regarding the association between sex and adverse drug events in contrast to our findings, Rademaker et al. (2001) found females had a 1.5 to 1.7 times greater risk of experiencing ADRs compared to males (Rademaker, 2001). However, Aljadhey from Saudi Arabia and Thiesen from the United Kingdom did not report a significant difference in ADR experiences among patients who were stratified based on sex (Thiesen et al., 2013, Aljadhey et al., 2016). But Holm’s study from Sweden showed that males reported experiencing ADRs that were more serious compared to females, which reflects our results (Holm et al., 2017).

In the present study, antimicrobial agents ranked the highest in terms of causing ADRs, which is consistent with other studies conducted locally and internationally. For example, a study in the Kingdom of Saudi Arabia (KSA) identified antibiotics as the most frequently implicated drugs in ADRs (Khan et al., 2012). Furthermore, studies conducted in Italy and India revealed antimicrobial drugs caused the greatest number of ADRs (Patidar et al., 2013, Salvo et al., 2013, Mudigubba et al., 2018).

Antimicrobial drugs are commonly prescribed in the KSA, which might explain the higher number of adverse events observed for this drug class. One Saudi study that confirms this explanation revealed that antibiotics were the most commonly prescribed drugs in the KSA (AlKhamees et al., 2018). However, this trend might diminish in the KSA in the future. In 2018, the MOH announced new enforcement of the Executive Regulations of Health Practice Law that prohibit dispensing antibiotics without a prescription to regulate antibiotic use, especially that of community pharmacies. In addition, the MOH warned that those who dispensed antibiotics without a prescription would be fined up to SR100,000 (26,654 $) (AlRukban and AlRuthia, 2020).

Furthermore, antibiotic stewardship programs have already been established in some hospitals in the KSA and have been effective in decreasing the overwhelming number of prescriptions for antibiotics, thus ensuring the rational prescription of antimicrobials. The expectation of a decrease in antimicrobial-related adverse events in the future, due to the previously mentioned advancements, should be investigated in future studies comparing the frequency of ADRs before and after implementing the new regulations (Alawi and Darwesh, 2016).

Two studies have highlighted the incidence of dermatologic events associated with use of ciprofloxacin (Mandal et al., 2004, Ada and Yilmaz, 2008). In the present study, we found ciprofloxacin-related ADRs ranged from skin hypersensitivity lesions to more systemic serious events, such as increased levels of transaminase enzymes, kidney injuries, severe hypotension, tachycardia, and convulsions.

As shown in Giardina, the most frequently used medications associated with ADRs were antibacterial agents (38.2%), followed by antithrombotic agents (21.7%). Among the antibiotic agents, quinolones (18.5%) and the penicillin group (7.0%) were the most frequently involved drugs (Giardina et al., 2018). These results paralleled ours.

We reported skin reactions and hepatic events with lopinavir and ritonavir. The reasons for the increased adverse events of this combination may be related to extensive use during 2020 due to its addition to the therapeutic protocol for treating COVID-19 patients in KSA. Similarly, this also happens with hydroxychloroquine, and most reactions were neurological reactions, cardiac events, and hepatic events. In addition, Cortegiani reported that high dosages of hydroxychloroquine as well as comorbidities and combinations with macrolides might increase adverse cardiac events (Cortegiani et al., 2020).
In Lombardi study conducted in Italy, 28.66% of the reported ADRs were severe and 26.86% led to hospitalization (Lombardi et al., 2018), which is similar to our findings. Likewise, our results were consistent with those Cortegiani 2020, where almost all patients experiencing ADRs recovered and improved (94.9%). Burggraaf warned of the sudden death of asthma patients during

Table 2
Adverse events outcome among different age groups.

| Age  | Recovered | Did Not Recover | Unknown | Fatal |
|------|-----------|----------------|---------|-------|
|      | N      | %     | N     | %     | N      | %     | N      | %     |
| 0–10 | 174    | 4.22  | 5     | 0.12  | 0      | 0     | 0      | 0     |
| 11–20| 84     | 2.04  | 3     | 0.07  | 2      | 0.04  | 0      | 0     |
| 21–30| 599    | 14.5  | 7     | 0.17  | 0      | 0     | 0      | 0     |
| 31–40| 675    | 16.4  | 12    | 0.29  | 0      | 0     | 0      | 0     |
| 41–50| 768    | 18.6  | 9     | 0.21  | 0      | 0     | 0      | 0     |
| 51–60| 544    | 13.2  | 10    | 0.24  | 1      | 0.024 | 1      | 0.024 |
| 61–70| 894    | 21.7  | 22    | 0.53  | 0      | 0     | 0      | 0     |
| 71–80| 197    | 4.78  | 32    | 0.77  | 1      | 0.024 | 1      | 0.024 |
| 81–90| 33     | 0.8   | 24    | 0.58  | 0      | 0     | 0      | 0     |
| >90  | 10     | 0.24  | 4     | 0.09  | 0      | 0     | 0      | 0     |
| Total| 3978   | 96.69 | 128   | 3.1   | 4      | 0.09  | 2      | 0.04  |

Fig. 1. Evaluation of gender-specific incidence and seriousness of adverse events.

Fig. 2. Association between the classification of drugs and seriousness of adverse events.
Top ten suspected drugs causing adverse drug reactions.

| Suspected Drug                        | Recovered | Did Not Recover | Total Reactions |
|--------------------------------------|-----------|----------------|-----------------|
| Ciprofloxacin                        | 280       | 36             | 316             |
| Lopinavir 200 mg + Ritonavir 50 mg   | 166       | 2              | 168             |
| Metformin Hydrochloride              | 146       | 14             | 160             |
| Amoxicillin, Clavulanic Acid         | 152       | 7              | 159             |
| Clarithromycin                       | 149       | 6              | 155             |
| Levofloxacin                         | 140       | 5              | 145             |
| Isotretinoin                         | 126       | 8              | 134             |
| Fingolimod HCl                       | 106       | 24             | 130             |
| Hydroxychloroquine Sulfate           | 55        | 10             | 65              |

**Table 3**

Association between systemic events, the Naranjo causality scale score and outcome of adverse events.

| Systemic event         | Possible* | Probable** | Definite*** | Outcome | Total 1144 |
|------------------------|-----------|------------|-------------|---------|------------|
| Cardiovascular         | 20        | 46         | 112         | 411     | 9.99       |
| Dermatological         | 17        | 80         | 1,94        | 394     | 9.58       |
| Endocrinological       | 10        | 24         | 95          | 290     | 7.05       |
| Gastrointestinal       | 65        | 1,58       | 286         | 695     | 6.78       |
| Gynecological          | 10        | 24         | 10          | 24     | 0.57       |
| Hematological          | 30        | 0.73       | 68          | 1,65    | 4.72       |
| Immunological          | 3         | 0.07       | 5           | 0.12    | 1.51       |
| Neurological & Psychiatric | 17   | 0.41       | 17          | 0.41    | 6.39       |
| Ophthalmic             | 0         | 0          | 7           | 0.17    | 1.51       |
| Respiratory            | 6         | 0.15       | 40          | 0.97    | 4.28       |
| Musculoskeletal        | 12        | 0.29       | 44          | 1,07    | 9.9        |
| Renal                  | 38        | 0.92       | 66          | 1,60    | 7.54       |
| Hepatic                | 46        | 1.12       | 190         | 4.62    | 6.81       |
| Other                  | 16        | 0.39       | 40          | 0.97    | 0.80       |
| Total                  | 290       | 7.05       | 938         | 22.8    | 2,886      |

**Table 4**

Suspected Drug | Recovered | Did Not Recover | Total Reactions
---|------------|----------------|-----------------|
Ciprofloxacin | 280 | 36 | 316 |
Lopinavir 200 mg + Ritonavir 50 mg | 166 | 2 | 168 |
Metformin Hydrochloride | 146 | 14 | 160 |
Amoxicillin, Clavulanic Acid | 152 | 7 | 159 |
Clarithromycin | 149 | 6 | 155 |
Levofloxacin | 140 | 5 | 145 |
Isotretinoin | 126 | 8 | 134 |
Fingolimod HCl | 106 | 24 | 130 |
Hydroxychloroquine Sulfate | 55 | 10 | 65 |

Possible*: 1 to 4 points, Probable**: 5 to 8 points, Definite***: 9 points or more.

hypoassociated with beta-2 adrenoceptor agonists, whereas death occurred in our study due to salbutamol use in one case (Burggraaf et al., 2001).

A Saudi interventional study found 10% of the reported ADRs were definite. At the same time, the remaining ADRs were possible or probable (Alshammari et al., 2015), and these results differ from ours. Most ADRs were definitely related to antimicrobial, hematological, neurological, and cardiovascular drugs. In addition, the prescribers typically had extensive experience with these medications, which increases the relative ease of identifying any adverse event and relating it to the drug used.

We also found that the most definite ADRs associated with cardiac events were related to fluoroquinolones and macrolides. These results were similar to Postma’s study findings: Cardiac events occurred in 3.8%, 2.6%, and 4.1% of patients exposed to ciprofloxacin, levofloxacin, and moxifloxacin, respectively, and in 5.3%, 7.2%, and 11.2% of patients exposed to azithromycin, clarithromycin, and erythromycin, respectively (Postma et al., 2019).

In the present study, the gastrointestinal system includes the most frequently affected organs, followed by liver and skin reactions, and most of these events related to the use of metformin and metronidazole. On the other hand, fluoroquinolones, isotretinoin, and fingolimod HCl induced hepatic reactions. However, according to the literature, the gastrointestinal system includes the most frequently affected organs, followed by the liver (Kouronian et al., 2009).

In this context, a study found that patients exposed to fluoroquinolones (ciprofloxacin, levofloxacin, and moxifloxacin) had a 20% increased likelihood of developing hepatotoxicity relative to persons who were not exposed to these agents (Alshammari et al., 2014). Additionally, liver test abnormalities occurred in up to 15% of patients on isotretinoin. However, marked elevations above three times the upper limit of normal or that require drug discontinuation are rare. Another study found a statistically significant increase in low-density lipoprotein and triglyceride levels in patients undergoing isotretinoin treatment (Kizilyel et al., 2014).

We applied several strategies to increase the number of ADR reports, such as establishing guidelines for monitoring, detecting, preventing, and reporting ADRs; providing education activities; promoting awareness campaigns; increasing motivation; establishing the role of a medication safety officer; increasing the participation of clinical pharmacists in rounds with physicians; allowing pharmacists to act immediately on ADR recognition; establishing medication counseling; establishing clinic and reconciliation programs; providing periodic ADR feedback reports to health care providers; establishing risk minimization programs for specific medications; and using social media to improve awareness.

Finally, based on our findings, efforts to minimize the occurrence of adverse drug events should be dedicated to achieving the safest and most effective drug therapies.

Likewise, pharmaceutical companies in the KSA need to understand the importance of implementing pharmacovigilance in a well-resourced department that can perform complete pharmacovigilance activities. The activities should also be applied according to the SFDA guidelines and regulations. Moreover, governmental and private hospitals that have not yet established
pharmacovigilance centers should establish them and incorporate the role of medication safety officers.

We suggest that integrating health information systems can help promote developing methods for detecting ADRs.

More important, patients using drugs known to cause life-threatening ADRs should be evaluated and monitored continuously. Similarly, older patients should also be prioritized in screening and monitoring because this group has a higher risk of developing ADRs. Moreover, we should not underestimate the importance of motivating pharmacists to understand their essential roles in decreasing the rate of ADRs through educating patients about the possible ADRs associated with suspected medications. In addition, patients should be educated about the available methods for reporting ADRs.

4.1. Study limitations

To our knowledge, this study is the first to explore the issue of ADRs in the Tabuk region. The present study revealed a high rate of ADRs in the region. However, some limitations are worth mentioning. First, this retrospective study was based on reports from patients and health care providers and not on clinical observations and judgments. Thus, the ADRs might have been underreported and the symptoms that occurred with the drug being used might have been misjudged. In addition, some patients might have undergoing conditions that could contribute to the presence of a complaint or finding. However, this limitation is common in any ADR survey, even prospectively designed studies. Second, the study targeted the population in the Tabuk region, and thus, the results are not generalizable to the Saudi population.

4.2. Conclusions

The regional spontaneous report database strengthens the importance and role of ADRs in monitoring the safety information of marketed drugs and their value related to investigating the signs associated with ADRs. Frequently used medications are associated with a higher risk of developing severe and serious events, especially antimicrobials, cardiovascular, and hematologic drugs. Therefore, education activities and campaigns regarding strategies to identify and report any suspected ADRs are essential to avoid underreporting adverse drug events. In addition, the reported high rate of ADRs might be significantly reduced through the cooperation of health authorities, health care professionals, hospitals, pharmaceutical companies, and the public.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

Ada, S., Yilmaz, S., 2008. Ciprofloxacin-induced generalized bullous fixed drug eruption. Indian J. Dermatol. Venereol. Leprol. 74, 511–512. https://doi.org/10.4101/0378-6323-44324.
Alawi, M.M., Darwesh, B., 2016. A stepwise introduction of a successful antimicrobial stewardship program. Experience from a tertiary care university teaching hospital in Western Saudi Arabia. Saudi medical journal 37 (12), 1350–1358. https://doi.org/10.15537/smjm.2016.12.15739.
Aljadhey, H., Mahmoud, M.A., Ahmed, Y., Sultana, R., Zouein, S., Alshammari, T.M., Mendi, N., Almalki, M., Alenzi, K.A., Alenzi, N.S., Alnami, M., AlRashid, A.A., 2018. Top 10 most used drugs in the Kingdom of Saudi Arabia 2016/2015. Saudi Pharm. J. 26 (2), 211–216. https://doi.org/10.1016/j.saphmj.2017.12.009.
Alshammari, T.M., Al-Kathiri, W.H., Louet, H.L., Aljdhey, H.S., 2015. Completeness of adverse drug reactions reporting of the Saudi adverse event reporting system. Saudi J. Med. Sci. J. 36 (7), 821–828.
Alshammari, T.M., Larrat, E.F., Monrill, H.J., et al., 2014. Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study. Am. J. Health Syst. Pharm. 71, 37–43. https://doi.org/10.2146/ajhp130165.
Alshammari, T.M., Mendi, N., Almalki, M., Alenzi, K.A., Asfoyad, Y., 2019. Pharmacovigilance Systems in Arab Countries: Overview of 22 Arab Countries. Drug Saf. 42 (7), 849–868. https://doi.org/10.1007/s40264-019-00870-4.
Beijer, H.J., de Blaeij, C.J., 2002. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm. World Sci. 24, 46–54. https://doi.org/10.1023/A:1015570104121.
Burggraaf, J., Westendorp, R.G., int Veen, J.C., et al., 2001. Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients. Thorax 56, 567–569. https://doi.org/10.1136/thorax.56.7.567.
Cortegiani, A., Ingoiglia, G., Ippolito, M., Giarratano, A., Einav, S., 2020. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J. Crit. Care 57, 279–283. https://doi.org/10.1016/j.jcrc.2020.03.005.
Gandhi, C., Cutoneo, P.M., Mocciaro, E., Russo, G.T., Mandruffino, G., Basile, G., Rapisarda, F., Ferrara, R., Spina, E., Arcoraci, V., 2018. Adverse drug reactions in hospitalized patients: results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study. Front. Pharmacol. 9. https://doi.org/10.3389/ fpfram.2018.00350.
Holm, L., Ekman, E., Jorsäter Blomgren, K., 2017. Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden. Pharmacoepidemiol. Drug Saf. 26 (3), 335–343. https://doi.org/10.1002/pds.4125.
Khan, L.M., Al-Harthi, S.E., Saadah, O.I., et al., 2012. Impact of pharmacovigilance on adverse drug reactions reporting in hospitalized internal medicine patients at Saudi Arabian teaching hospital. Saudi Med. J. 33, 863–868.
Kizjel, O., Metin, M.S., Elmas, O.F., et al., 2014. Effects of oral isotretinoin on liver and enzyme in liver. Cuts 94, 234–238.
Kourorian, Z., Fatfahi, Z., Pourpak, Z., et al., 2009. Adverse drug reactions in an Iranian department of adult infectious diseases. East Mediterr Health J. 15, 1351–1357.
Lavan, A.H., Gallagher, P., 2016. Predicting risk of adverse drug reactions in older adults. Ther. Adv. Drug Saf. 7 (1), 11–22. https://doi.org/10.1177/1753483415621044.
Lee, L.M., Carias, D.C., Gosser, R., et al., 2022. ASHP guidelines on adverse drug reaction monitoring and reporting. Am. J. Health Syst. Pharm. 79, e83–e89. https://doi.org/10.1093/ajhp/zxab324.
Lommatzsch, K., Crescioli, G., Bettiol, A., Macchi, E., Vitiello, A., Bonauti, R., Calvani, A.M., Masi, S., Lucenoforte, E., Mugelli, A., Giovannelli, L., Vannacci, A., 2018. Characterization of serious adverse drug reactions as cause of emergency department visit in children: a 5-years active pharmacovigilance study. BMC Pediatr. 18 (1). https://doi.org/10.1186/s12879-018-01074-4.
Mandal, B., Steward, M., Singh, S., et al., 2004. Ciprofloxacin-induced toxic epidermal necrolysis (TEN) in a nonagerian: a case report. Age Ageing 33, 405–406. https://doi.org/10.1093/ageing/ahl088.
K Medeghaba, M., Rajashekarachari, V., Dahya, S., 2018. Evaluation of Predisposing Factors Associated with Suspected Adverse Drug Reactions of Hospitalized Patients. JAY (10 (2), 202–207.
Murayama, H., Sakuma, M., Takahashi, Y., Morimoto, T., 2018. Improving the assessment of adverse drug reactions using the Naranjo Algorithm in daily practice: The Japan Adverse Drug Events Study. Pharmacol. Res. Perspect. 6 (1), e00373. https://doi.org/10.1002/prp2.373.
Patinar, D., Rajput, M.S., Nirala, N.P., Savitri, W., 2013. Implementation and evaluation of adverse drug reaction monitoring system in a tertiary care teaching hospital in Mumbai, India. Interdiscip. Toxicol. 6 (1), 41–46. https://doi.org/10.2478/intox-2013-0008.
Pillans, P.J., 2008. Clinical perspectives in drug safety and adverse drug reactions. Expert. Rev. Clin. Pharmacol. 1 (5), 695–705. https://doi.org/10.1586/17512433.1.5.695.
Postma, D.F., Spittino, C., van Werkhoven, C.H., van Elden, L.J.R., Oosterheert, J.J., Bentien, M.J.M., 2019. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial. BMC Infect. Dis. 19 (1). https://doi.org/10.1186/s12879-018-3630-7.
Radmaker, M., 2001. Do women have more adverse drug reactions? Am. J. Clin. Dermatol. 2 (6), 349–351. https://doi.org/10.1023/A:10128071-20010206-00001.
Salvo, F., Miroddi, M., Alibrandi, A., Calapai, F., Caffeo, V., Mancari, F., Gangemi, S., Caputi, A.P., Calapai, G., 2013. Attitudes and opinion about adverse drug events of women living in a city of south Italy. Pharmacology 91 (3–4), 173–177. https://doi.org/10.1002/sfd.201200001.
sFDA, S. F. D. A., 2022. Adverse Drug Reactions Report Form. https://ade.sfda.gov.sa/Request/AdeRequestPublic.
Thiesen, S., Conroy, E.J., Bellis, J.R., Bracken, L.E., Bird, K.A., Duncan, J.C., Cresswell, L., Kirkham, J.J., Peak, M., Williamson, P.R., Nunn, A.J., Turner, M.A., Pirmohamed, M., Smyth, R.L., 2013. Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children - a prospective observational cohort study of 6,601 admissions. BMC Med. 11 (1). https://doi.org/10.1186/1741-7015-11-237.

Prasanth, Y., Narendra, B., Upendra, K., Rajesh, K., Hemanth, D.N., 2020. A review on adverse drug reactions monitoring and reporting. https://doi.org/10.31838/ijprt/10.01.09.